ClinicalTrials.gg
RecruitingNCT05610865Updated Dec 31, 2024

Efficacy of Adipose Tissue Derived Stem Cells for the Treatment of Diabetic Foot Ulcers

A Phase 1 interventional study of Control; Standard-of-care management and Only PRP injection in Diabetic Foot Ulcer, Diabetes Mellitus and Diabetic Foot, sponsored by University of the Punjab. Recruiting at 1 site in Pakistan. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-12-31.

Sponsored by University of the Punjab · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 11 months after the study started (first participant enrolled Nov 2020, registered Oct 2022).
  • Started Nov 2020; still recruiting 6 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
20 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Diabetic Foot with a site in Pakistan — 5 open to participants now, 7 under way, 1 of them phase 3. Diabetic Foot · Pakistan.

Planned enrollment
14th of 16
28 · median 94
Started
2020
with 2 others
Phase 1
Only one
of the 17
Registered
5th of 17
by date

Among the 17 studies in Diabetic Foot with a site in Pakistan, this one is the 14th largest by planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2020, is the only one in phase 1, and was the 5th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

5 of the 17 studies in Diabetic Foot with a site in Pakistan are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 20 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Diabetic Foot with a site in Pakistan, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the therapeutic efficacy of uncultured adipose derived stromal vascular fraction (SVF) and cultured adipose derived stem cells (ASCs) both supplemented with platelet rich plasma (PRP) to treat chronic diabetic foot ulcers. It will increase the pragmatic potential of both types of cells as PRP is rich in survival and chemotactic factors. Moreover, the autologous nature of the proposed study will ensure safety of its use in diabetic patients and will unveil the more effective therapeutic option for treatment of foot ulcer wounds.

Read the detailed description

Under local or general anesthesia, autologous fat will be harvested by using a manual aspiration or syringe-assisted technique. SVF and ASCs isolation from autologous lipoaspirates will be done by enzymatic digestion method (collagenase Type-1 solution for 45 minutes at 37°C). Cell quality assessment will be done prior to transplantation by trypan blue exclusion assay and total populations and fractions of cells identified by immunocytochemistry / flow cytometry. PRP will be derived by centrifugation from 50-100ml blood collected in anticoagulant carrying bag, from patient at the day of transplantation. The injection volume will depend on the wound area of each patient. 2 million cells/ 0.5 ml PRP will be mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone \& inside of wound surface bed.

03

Conditions studied

  • Diabetic Foot Ulcer
  • Diabetes Mellitus
  • Diabetic Foot
  • Diabetic Foot Infection
  • Diabetic Foot Ulcer Neuropathic
  • Foot Ulcer Due to Type 1 Diabetes Mellitus
  • Foot Ulcer Due to Type 2 Diabetes Mellitus
  • Foot Ulcer
  • Diabetes Complications
  • Chronic Diabetic Ulcer of Left Foot
  • Chronic Diabetic Foot Ulcer of Right Foot

Keywords

  • Stromal vascular fraction (SVF), Adipose derived stem cells (ASCs), Diabetic foot ulcer (DFU), Platelet rich plasma (PRP)
04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 1 or Type 2 Diabetes Mellitus
  • Age 20-60 years (Male/Female)
  • 20-30 kg/m2
  • Suitable for liposuction
  • Condition or Disease: Diabetic Neuropathy
  • Wound Type: Chronic foot ulcer
  • Approx. wound area: 2 cm2 - 8 cm2
  • Wound Condition should be of Wagner's grade I (Limited to soft tissue)
  • Duration of wound persistence: 6-24 Weeks
  • Transcutaneous oxygen pressure > 30 mmHg, and an ankle brachial pressure index > 0.5.
  • Already following an adequate off-loading method
  • Provided signed

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled hyperglycemia (HbAlc > 9%)
  • Presence of severe clinical sign of infection
  • Inability to tolerate off-loading, and poor prognosis diseases including malignant tumors.
  • Serious chronic disease i.e hepatic, heart, renal, pulmonary diseases
  • Patients with critical limb ischemia and osteomylitis
  • Withdrawal of
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Active comparator
    Control; Standard-of-care management

    Saline dressing will be done as a routine care management.

    Other: Control; Standard-of-care management

  • Experimental
    Only PRP injection

    Only PRP will be injected at the wound site.

    Biological: Only PRP injection

  • Experimental
    PRP + SVF injection

    SVF pellet mixed with PRP will be injected at the wound site after adjusting number of cells.

    Biological: PRP + SVF injection

  • Experimental
    PRP + ASCs injection

    Cultured ASCs mixed with PRP will be injected at the wound site after adjusting number of cells.

    Biological: PRP + ASCs injection

Interventions

  • OtherControl; Standard-of-care management

    Patients will undergo conventional wound care management.

  • BiologicalOnly PRP injection

    Only PRP injected / cm2 intradermally at the border zone \& inside of wound surface bed.

  • BiologicalPRP + SVF injection

    Uncultured cells (SVF) along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone \& inside of wound surface bed.

  • BiologicalPRP + ASCs injection

    Cultured ASCs along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone \& inside of wound surface bed.

06

What researchers measure

Primary outcomes

  1. Interview and visual inspection of ulcers recovery rate

    This will be done in terms of diameter (cm2) of wounds, monitored in both cell transplanted and standard care patients after week interval till 3 months.

    Time frame: 3 months

Secondary outcomes

  1. Percentages (%) of wound closure rate (with respect to time) will be assessed.

    Change in wound size (cm2) will be determined

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
  • Stem Cell Laboratory, Jinnah Burn and Reconstructive Surgery Center (JB&RSC)
    Lahore, Punjab 54550, Pakistan
    Recruiting
    • Dr. Moazzam Nazeer Tarar, Plastic Surgeon MBBS/ FRCS · Contactmntarar@gmail.com · +92-300-8423139
08

References and documents

Publications

  • Shao S, Pan R, Chen Y. Autologous Platelet-Rich Plasma for Diabetic Foot Ulcer. Trends Endocrinol Metab. 2020 Dec;31(12):885-890. doi: 10.1016/j.tem.2020.10.003. Epub 2020 Nov 13. PubMed 33199085 ↗
  • Nolan GS, Smith OJ, Heavey S, Jell G, Mosahebi A. Histological analysis of fat grafting with platelet-rich plasma for diabetic foot ulcers-A randomised controlled trial. Int Wound J. 2022 Feb;19(2):389-398. doi: 10.1111/iwj.13640. Epub 2021 Jun 24. PubMed 34169656 ↗
  • Carstens MH, Quintana FJ, Calderwood ST, Sevilla JP, Rios AB, Rivera CM, Calero DW, Zelaya ML, Garcia N, Bertram KA, Rigdon J, Dos-Anjos S, Correa D. Treatment of chronic diabetic foot ulcers with adipose-derived stromal vascular fraction cell injections: Safety and evidence of efficacy at 1 year. Stem Cells Transl Med. 2021 Aug;10(8):1138-1147. doi: 10.1002/sctm.20-0497. Epub 2021 Apr 7. PubMed 33826245 ↗
  • Qin HL, Zhu XH, Zhang B, Zhou L, Wang WY. Clinical Evaluation of Human Umbilical Cord Mesenchymal Stem Cell Transplantation After Angioplasty for Diabetic Foot. Exp Clin Endocrinol Diabetes. 2016 Sep;124(8):497-503. doi: 10.1055/s-0042-103684. Epub 2016 May 24. PubMed 27219884 ↗
  • Han SK, Kim HR, Kim WK. The treatment of diabetic foot ulcers with uncultured, processed lipoaspirate cells: a pilot study. Wound Repair Regen. 2010 Jul-Aug;18(4):342-8. doi: 10.1111/j.1524-475X.2010.00593.x. Epub 2010 May 11. PubMed 20492632 ↗
  • Didangelos T, Koliakos G, Kouzi K, Arsos G, Kotzampassi K, Tziomalos K, Karamanos D, Hatzitolios AI. Accelerated healing of a diabetic foot ulcer using autologous stromal vascular fraction suspended in platelet-rich plasma. Regen Med. 2018 Apr;13(3):277-281. doi: 10.2217/rme-2017-0069. Epub 2018 May 1. PubMed 29715071 ↗
  • Prakasam N, Prabakar MS, Reshma S, Loganathan K, Senguttuvan K. A clinical study of platelet rich plasma versus conventional dressing in management of diabetic foot ulcers. International Surgery Journal. 2018 Sep 25;5(10):3210-6.
  • Alvaro-Afonso FJ, Sanz-Corbalan I, Lazaro-Martinez JL, Kakagia D, Papanas N. Adipose-Derived Mesenchymal Stem Cells in the Treatment of Diabetic Foot Ulcers: A Review of Preclinical and Clinical Studies. Angiology. 2020 Oct;71(9):853-863. doi: 10.1177/0003319720939467. Epub 2020 Jul 29. PubMed 32723090 ↗
  • Khan A, Junaid N. Prevalence of diabetic foot syndrome amongst population with type 2 diabetes in Pakistan in primary care settings. J Pak Med Assoc. 2017 Dec;67(12):1818-1824. PubMed 29256523 ↗
  • Yin S, Yang X, Bi H, Zhao Z. Combined Use of Autologous Stromal Vascular Fraction Cells and Platelet-Rich Plasma for Chronic Ulceration of the Diabetic Lower Limb Improves Wound Healing. Int J Low Extrem Wounds. 2021 Jun;20(2):135-142. doi: 10.1177/1534734620907978. Epub 2020 Mar 4. PubMed 32131655 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Dec 2025, 61 months after the start.

Of 26 phase 1 interventional studies under Diabetic Foot, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 43. This study's planned 61 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2022
First posted
Nov 9, 2022
StartActual
Nov 20, 2020
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Dec 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05610865
Lead sponsor
University of the Punjab
Collaborators
Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Higher Education Commission (Pakistan), Jinnah Burn and Reconstructive Surgery Centre, Lahore
Responsible party
Azra Mehmood (Associate Professor, University of the Punjab) — Principal investigator
First posted
Nov 9, 2022
Start date
Nov 20, 2020
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Dec 31, 2024

Study contacts

Azra Mehmood, PhD
Contact
azra_mehmood@hotmail.com
+92-333-4107008
Amna Arif, M.Phil.
Contact
amnaarif.qureshi@gmail.com
+92-333-4161068
Azra Mehmood, PhD
principal investigator · Center of Excellence in Molecular Biology (CEMB, University of the Punjab, Lahore
Sheikh Riazuddin, PhD
study director · Jinnah Burn and Reconstructive Surgery Center (JB&RSC), Lahore

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion